Systemic targeted delivery of antisense with perflourobutane gas microbubble carrier reduced neointimal formation in the porcine coronary restenosis model

Cardiovascular Radiation Medicine

Volumn 4, Issue 3, 2003, Pages 152-159

  Kipshidze, Nicholas N ^a   Porter, Thomas R ^b   Dangas, George ^a   Yazdi, Hamid ^c   Tio, Fermin ^d   Xie, Feng ^b   Hellinga, David ^c   Fournadjiev, Jana ^c   Wolfram, Roswitha ^c   Seabron, Rufus ^c   Waksman, Ron ^c   Abizaid, Alexander ^e   Roubin, Gary ^a   Iyer, Sriram ^a   Leon, Martin B ^a   Moses, Jeffrey W ^a   Iversen, Patrick ^f  

^a CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c Research Inst   (United States)

^d SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^e INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^f AVI BIOPHARMA INC   (United States)

Author keywords

Antisense; Nanoparticles; Restenosis; Stents

Indexed keywords

AVI 4126; BUTANE; FLUOROCARBON; MORPHOLINE DERIVATIVE; PERFLUORO COMPOUND; POLOXAMER;

ANIMAL EXPERIMENT; ARTERY INTIMA PROLIFERATION; ARTICLE; CATHETER; CORONARY ARTERY OBSTRUCTION; DRUG DELIVERY SYSTEM; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; RESTENOSIS; STENT; SWINE; WESTERN BLOTTING;

EID: 10744229758     PISSN: 15221865     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1522-1865(03)00184-7     Document Type: Article

References (25)

1. Speir E., Epstein S.E. Inhibition of smooth muscle cell proliferation by an antisense oligodeoxynucleotide targeting the messenger RNA encoding proliferating cell nuclear antigen. Circulation. 86:1992;538-547.
2. Simons M., Edelman E.R., DeKeyser J.L., Langer R., Rosenberg R.D. Antisense c-myb oligonucleotides inhibit arterial smooth muscle cell accumulation in vivo. Nature. 359:1992;67-70.
3. Gunn J., Holt C.M., Francis S.E., Shepherd L., Grohmann M., Newman C.M., Crosman D.C., Cumberland D.C. The effect of oligonucleotides to c-myb on vascular smooth muscle cell proliferation and neointima formation after porcine coronary angioplasty. Circ Res. 80:1997;520-531.
4. Zalewski A., Shi Y., Mannion JDet al. Synthetic DNA-based compounds for the prevention of coronary restenosis: current status and future challenges. Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors. 1998;363-393 (Ed. Eric Wickstrom), Marcel Dekker, New York (NY).
5. Kutryk M.J., Foley D.P., van den Brand M., Hamburger J.N., van der Giessen W.J., deFeyter P.J., Bruining N., Sabate M., Serruys P.W. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J Am Coll Cardiol. 39(2):2002;281-287.
6. Stein C., Cheng Y. Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science. 261:1993;1004-1012.
7. Shocman R.L., Hartig R., Huang Y., Grub S., Traub P. Fluorescence microscopic comparison of the binding of phosphodiester and phosphothioate oligodeoxyribonucleotides to subcellular structures, including intermediate filaments, the endoplasmic reticulum and the nuclear interior. Antisense Nucleic Acid Drug Dev. 7:1997;291.
8. Hudziak R.M., Barofsky E., Barofsky D.F., Weller D.L., Huang S.B., Weller D.D. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev. 6:1996;267-272.
9. Summerton J., Stein D., Huang B., Matthews P., Weller D., Partridge M. Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev. 7:1997;63-75.
10. Taylor M.F., Paulaskis J.D., Weller D.D., Kobzik L. In vivo efficacy of morpholino modified oligomers directed against tumor necrosis factor-a mRNA. J Biol Chem. 29:1996;17452-17455.
11. Kipshidze N., Keane E., Stein D., Chawla P., Skrinska V., Shankar L.R., Khanna A., Komorowski R., Haundenschild C., Iversen P., Leon M.B., Kealan M.H., Moses J. Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheter Cardiovasc Interv. 54(2):2001;247-256. Oct.
12. Kipshidze N.N., Kim H.S., Iversen P., Yazdi H.A., Bhargava B., New G., Mehran R., Tio F., Haundenschild C., Dangas G., Stone G.W., Iyer S., Roubin G.S., Leon M.B., Moses J.W. Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model. J Am Coll Cardiol. 39:2002;1686-1691.
13. Lindner J.R., Ismail S., Spotnitz W.D., Skyba D.M., Jayaweera A.R., Kaul S. Albumin microbubble persistence during myocardial contrast echocardiography is associated with microvascular endothelial glycocalyx damage. Circulation. 98:1998;2187-2194.
14. Lindner J.R., Coggins M.P., Kaul S., Klibanov A.L., Bradenburger G.H., Ley K. Microbubble persistence in the microcirculation during ischemia/reperfusion and inflammation is caused by integrin- and complement-mediated adherence to activated leukocytes. Circulation. 101:2000;668-675.
15. Lindner J.R., Dayton P.A., Coggins M.P., Ley K., Song J., Ferrara K., Kaul S. Noninvasive imaging of inflammation by ultrasound detection of phagocytosed microbubbles. Circulation. 2000;531-538.
16. Porter T.R., Hiser W., Kricsfeld D., Deligonul U., Xie F., Iversen P., Radio S. Inhibition of carotid artery neointimal formation with intravenous microbubbles. Ultrasound Med Biol. 2001.
17. Shohet R.V., Chen S., Zhou Y.T., Wang Z., Meidell R.S., Unger R.H., Grayburn P.A. Echocardiographic destruction of albumin microbubbles directs gene delivery to the myocardium. Circulation. 101:2000;2554-2556.
18. Summerton J., Weller D. Morpholino antisense oligomers: design, preparation and properties. Antisense Nucleic Acid Drug Dev. 7:1997;63-70.
19. Larrouy B., Boiziau C., Toulme J. RNAse H is responsible for non-sequence specific inhibition of in vitro translation by 2′-0-alkyl chimeric oligonucleotides: high affinity or selectivity, a dilemma to design antisense oligomers. Nucleic Acids Res. 23:1995;3434-3440.
20. Kornowski R., Hong M.K., Tio F.O., Bramwell O., Wu H., Leon M.B. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 31:1998;224-230.
21. Suzuki T., Kopia G., Hayashi S., Bailey L.R., Llanos G., Wilensky R., Klugherz B.D., Papandreou G., Narayan P., Leon M.B., Yeung A.C., Tio F., Taso P.S., Falotico R., Carter A.J. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 104(10):2001;1188-1193.
22. Farb A., Heller Phillip F., Shroff S., Cheng L., Kolodgie F.D., Carter A.J., Scott D.S., Froehlich J., Virmani R. Pathological analysis of local delivery of Paclitaxel via a polymer-coated stent. Circulation. 104:2001;473-479.
23. Sousa J.E., Costa M.A., Abizaid A., Abizaid A.S., Feres F., Pinto I.M., Seixas A.C., Staico R., Mattos L.A., Sousa A.G., Falotico R., Jaeger J., Popma J.J., Serruys P.W. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 103(2):2001;192-195.
24. Morice M.C., Serruys P.W., Sousa JEet al. A randomized comparison of sirolimus-eluting stent with a standard stent for revascularization. N Engl J Med. 346:2002;1773-1779.
25. Moses J.W., Leon M.B., Popma JJet al. Angiographic and clinical outcomes after a sirolimus-eluting stent compared to a standard stent in patients with native coronary artery stenoses. N Engl J Med. 349:2003;1315-1323.